Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with <em>MET</em> mutations or amplification. EORTC 90101 CREATE trial. Have a read: https://www.m3india.in/contents/journal/crizotinib-achieves-long-lasting-disease-control?utm_campaign=unset&utm_medium=share&utm_source=ref_wa